F S&P 500
5,244.50 +5.50 (+0.10%) F Dow Jones
39,587.00 +51.00 (+0.13%) F Nasdaq
18,228.25 +13.75 (+0.08%) E-mini Russell 2000 Index Futur
2,087.00 +2.90 (+0.14%) Petróleo
79.84 +0.58 (+0.73%) Oro
2,361.60 +21.30 (+0.91%)
Harmony Biosciences Holdings, Inc. (HRMY)
Fuera de horario:
Harmony Biosciences Holdings, Inc.
630 West Germantown Pike
Suite 215
Plymouth Meeting, PA 19462
United States
484 539 9800
https://www.harmonybiosciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 246
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jeffrey S. Aronin | Founder & Non-Executive Chairman | 185.67k | N/D | 1968 |
| Dr. Jeffrey M. Dayno M.D. | President, CEO & Director | 1.26M | N/D | 1957 |
| Mr. Jeffrey Dierks M.B.A. | Executive VP & Chief Commercial Officer | 830.75k | N/D | 1972 |
| Mr. Andrew Serafin J.D., M.B.A. | Executive VP & Chief Strategy Officer | 647.42k | N/D | 1975 |
| Dr. Kumar Budur M.D., M.S. | Executive VP & Chief Medical Officer | 760.81k | N/D | N/D |
| Mr. David Bradshaw | Head of Technical Operations | N/D | N/D | N/D |
| Luis Sanay | Head of Investor Relations | N/D | N/D | N/D |
| Mr. Christian Ulrich | General Counsel & Corporate Secretary | N/D | N/D | N/D |
| Ms. Tricia Glover | Chief Compliance Officer | N/D | N/D | N/D |
| Ms. Audrey Murphy SPHR | Vice Presidet of Human Resources | N/D | N/D | N/D |
Descripción
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Harmony Biosciences Holdings, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 9; Derechos del accionista: 8; Compensación: 8.
